PostDose.

Guides

Is Semaglutide Legal? Brand, Generic and Compounded Status per the FDA (2026)

Semaglutide is FDA-approved as Wegovy, Ozempic and Rybelsus, and a first generic has only tentative approval. Compounded semaglutide is a much narrower story. Current FDA status with sources and red flags.

Semaglutide is the most searched GLP-1 in Houston, and the one where the word “legal” hides the most confusion. The molecule is an approved drug. What varies is the version a clinic hands you: brand, compounded, or something labeled “research.” Each has a different legal footing.

What it is

Semaglutide is a GLP-1 receptor agonist, given as a weekly injection (Wegovy, Ozempic) or taken daily by mouth (Rybelsus). It is a prescription drug. It is not a supplement.

The FDA status, in order

Approved, under several brand names. We queried Drugs@FDA through the public openFDA API on October 12, 2026. Semaglutide appears under these Novo Nordisk applications, with the original submission date FDA records for each:

  • NDA 209637, Ozempic injection (December 5, 2017)
  • NDA 213051 and NDA 213182, Rybelsus and Ozempic-branded tablets (September 20, 2019 and January 16, 2020)
  • NDA 215256, Wegovy injection (June 4, 2021)
  • NDA 218316, Wegovy tablets (December 22, 2025)

DailyMed, the National Library of Medicine’s labeling database, returned 9 semaglutide labels, including repackager listings.

A generic exists on paper, but is not approved to market. The same query shows ANDA 220314, a semaglutide injection from Apotex, with a tentative approval dated April 7, 2026. Tentative approval is not final approval, so it does not mean a generic is on pharmacy shelves.

Shortage over, so the wide compounding window closed. FDA’s page on compounder policies states that the semaglutide injection shortage was determined resolved on February 21, 2025, and that enforcement discretion for state-licensed pharmacies and physicians compounding under section 503A ended April 22, 2025 (outsourcing facilities under 503B: May 22, 2025). The same page, last modified April 1, 2026, says semaglutide does not currently appear on FDA’s drug shortage list or the 503B bulks list. It also says that adding another ingredient, such as vitamin B12, can still leave a product “essentially a copy” of the brand drug if the strengths are within 10% and the route is the same.

FDA’s stance today. FDA’s page “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” (content current as of October 1, 2026) says compounded drugs “should only be used in patients whose medical needs cannot be met by an FDA-approved drug.” It also states:

  • Semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved drugs, and FDA is “not aware of any lawful basis for their use in compounding.”
  • FDA has received reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide.
  • As of May 31, 2026, FDA had received 990 adverse event reports associated with compounded semaglutide. FDA notes that pharmacies that are not outsourcing facilities are not required to report, so the true number is likely higher, and that a report does not prove the drug caused the event.
  • FDA has warned companies selling semaglutide labeled “for research purposes” or “not for human consumption” while giving human dosing instructions.

We checked FDA’s 503A bulks page (last modified May 14, 2026) and Category 2 safety-risk page (last modified April 22, 2026): semaglutide appears on neither.

What this means for a clinic menu

When a clinic says “semaglutide,” ask which of four things it means: brand Wegovy, Ozempic or Rybelsus from a pharmacy; a patient-specific compounded prescription with a documented reason the brand cannot work; a salt form such as sodium or acetate; or a “research” vial. Only the first is plainly straightforward. The second is narrow and under FDA scrutiny. The last two have no lawful basis according to FDA.

Red flags we check for

  • A “semaglutide program” that never says brand or compounded, or which pharmacy fills it.
  • Claims that compounded semaglutide is “the same as” Wegovy, which FDA lists as a telehealth red flag.
  • Salt forms (sodium, acetate) or “research use only” labeling.
  • Multi-dose vials without clear dosing instructions. FDA says to discard a multi-dose vial within 28 days of first use.
  • No named prescriber we can confirm in the NPI registry.

Six clinics in our dataset currently carry the verified status, and five of them list semaglutide programs, including Lifelong Weight Loss and NeuMed, which name brand products such as Wegovy or Ozempic on their own sites. Browse the verified clinics in Houston, read how brand and compounded GLP-1s differ, and see our full verification standard.

Sources: FDA, Drugs@FDA via openFDA (api.fda.gov/drug/drugsfda.json, semaglutide), retrieved October 12, 2026. NLM DailyMed API (spls.json?drug_name=semaglutide, 9 results), retrieved October 12, 2026. FDA, “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize”, modified April 1, 2026, retrieved October 12, 2026. FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”, content current as of October 1, 2026, retrieved October 12, 2026. FDA, “Bulk Drug Substances Used in Compounding Under Section 503A”, modified May 14, 2026. FDA, “Certain Bulk Drug Substances … That May Present Significant Safety Risks”, modified April 22, 2026.

This article is independent editorial content, not medical advice. See our medical disclaimer.